Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer Disease Clinical Trial Recruitment

Researchers wanted to gather information on use of direct-to-consumer APOE genetic testing usage among enrollees of the University of California Irvine Consent-to-Contact Registry. The study assessed usage among enrollees and attitudes toward using this information in clinical trial recruitment. The results demonstrated that matching participants to trials using direct-to-consumer testing of APOE results could help streamline recruitment for Alzheimer’s disease prevention trials.

Ryan MM, et al. Using direct-to-consumer genetic testing results to accelerate Alzheimer disease clinical trial recruitment. Alzheimer Disease Associated Disorders. 2020. ePub Oct. 14. doi: 10.1097/WAD.0000000000000421.